Literature DB >> 11146121

Induction and alternative splicing of delta isoform of Ca(2+)/calmodulin-dependent protein kinase II during neural differentiation of P19 embryonal carcinoma cells and during brain development.

H Donai1, T Murakami, T Amano, Y Sogawa, T Yamauchi.   

Abstract

Since the expression of Ca(2+)/calmodulin-dependent protein kinase II (CaM kinase II) is regulated during brain development, the developmental change of the enzyme was investigated during the neural differentiation of murine P19 embryonal carcinoma cells. CaM kinase II activity was induced during the differentiation of P19 cells treated with retinoic acid. Expression of the enzyme was induced 2 days after the treatment and maximized at 5 days. The enzyme activity increased about approximately 8-fold. The enzyme protein was shown to differ between differentiated and undifferentiated cells. The delta isoform of CaM kinase II was found as the major isoform in P19 cells by immunoblotting and reverse transcription-polymerase chain reaction (RT-PCR). A total of four and three alternatively spliced variants of delta isoform were detected in P19 cells by RT-PCR analysis and by immunoblotting, respectively. Although multiple alternatively spliced forms have been reported, the major splice variants of delta isoform in differentiated cells were delta l and delta 9 isoforms, which were specifically detected in differentiated cells. In undifferentiated cells, the major splice variant corresponded to delta 2 isoform. These results indicated that the expression of delta isoform of CaM kinase II was induced, and the splicing pattern of the isoform changed, during neural differentiation. Cell type distinctive changes of splicing pattern of delta isoform were also observed not only during differentiation of cultured neuronal cells, but also during development of rat forebrain and cerebellum.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11146121     DOI: 10.1016/s0169-328x(00)00221-7

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  6 in total

1.  Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C deltaVIII (PKCdeltaVIII) isoform via splicing factor SC35.

Authors:  Hercules Apostolatos; André Apostolatos; Timothy Vickers; James E Watson; Shijie Song; Fernando Vale; Denise R Cooper; Juan Sanchez-Ramos; Niketa A Patel
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

2.  Increased expression of calcium/calmodulin-dependent protein kinase type II subunit δ after rat traumatic brain injury.

Authors:  Mingyang Zhang; Haiyan Shan; Zhenyong Gu; Donglin Wang; Tao Wang; Zhiwei Wang; Luyang Tao
Journal:  J Mol Neurosci       Date:  2011-11-03       Impact factor: 3.444

3.  Effects of perinatal lipopolysaccharide (LPS) exposure on the developing rat brain; modeling the effect of maternal infection on the developing human CNS.

Authors:  M Xu; Z L Sulkowski; P Parekh; A Khan; T Chen; S Midha; T Iwasaki; N Shimokawa; N Koibuchi; A M Zavacki; E M Sajdel-Sulkowska
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

4.  Calcium-calmodulin-dependent protein kinase II isoforms differentially impact the dynamics and structure of the actin cytoskeleton.

Authors:  Laurel Hoffman; Madeline M Farley; M Neal Waxham
Journal:  Biochemistry       Date:  2013-02-04       Impact factor: 3.162

5.  Role of Ca2+/calmodulin-dependent kinase II-IRAK1 interaction in LMP1-induced NF-κB activation.

Authors:  Jung-Eun Kim; Sang Yong Kim; Sue Yeon Lim; Elliott Kieff; Yoon-Jae Song
Journal:  Mol Cell Biol       Date:  2013-11-18       Impact factor: 4.272

6.  Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.

Authors:  Koichi Suenaga; Kuang-Yung Lee; Masayuki Nakamori; Yoshiki Tatsumi; Masanori P Takahashi; Harutoshi Fujimura; Kenji Jinnai; Hiroo Yoshikawa; Hongqing Du; Manuel Ares; Maurice S Swanson; Takashi Kimura
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.